Skip to main content
SpringerLink
Log in

Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372(4):311–319

    Article  PubMed  Google Scholar 

  2. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A (2016) Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283–1294

    Article  CAS  PubMed  Google Scholar 

  3. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH (2016). Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol Jun 27

  4. Chen RW, Zinzani PL, Fanale MA, Armand P, Johnson N, Ribrag V, Radford JA, Tomita A, Shipp MA, Wang Y, Ricart AD, Balakumaran A, Moskowitz CH (2016). Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study. J Clin Oncol 34 (suppl; abstr 7555)

  5. Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647–651

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Queen Mary Hospital, Professorial Block, Pokfulam Road, Hong Kong, China

    Yu-Yan Hwang & Yok-Lam Kwong

  2. Department of Diagnostic Radiology, Queen Mary Hospital, Hong Kong, China

    Pek-Lan Khong

Authors
  1. Yu-Yan Hwang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pek-Lan Khong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yok-Lam Kwong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yok-Lam Kwong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hwang, YY., Khong, PL. & Kwong, YL. Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96, 1219–1220 (2017). https://doi.org/10.1007/s00277-017-3007-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3007-9

Keywords

Search

Navigation